Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation

Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study)

Continuous-flow left ventricular assist devices (LVAD) move blood from the left ventricle (the largest chamber of the heart) to the aorta (the body's main artery) to help the heart better meet the needs of the body and to improve survival for patients with advanced heart failure (HF). The ability of the right ventricle (the large chamber on the right side of the heart) to keep up with the improved blood flow following LVAD greatly effects how well a person does following surgery. It is understood that a high pulmonary artery pressure (pressure in the blood vessel that takes blood from the right side of the heart to the lungs) measured before surgery, indicates that a higher risk of right heart failure exists after LVAD implantation.

This is important because right heart failure after surgery is related to longer intensive care unit (ICU) and hospital stays, increased morbidity (other health problems) including organ failure and worse outcomes following heart transplant, and increased death rates.

Sildenafil (Revatio®) has been approved by Health Canada in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs) in patients with connective tissue disease. Sildenafil has not yet been approved by Health Canada for the treatment of pulmonary hypertension in heart failure. Sildenafil lowers blood pressure in the lungs and lessens the workload of the right ventricle (the right side of the heart). The purpose of this study is to determine if lowering blood pressure in the lungs, in heart failure patients at risk for developing right heart failure after LVAD implant, lowers the incidence of right heart failure, shortens ICU and hospital stays and reduces morbidity (other health problems) and mortality (death rates).

This is an open label, single arm study. Everyone who participates in this study will receive sildenafil before and after LVAD surgery. It is expected that 24 patients who are scheduled to have LVAD implantation for advanced heart failure will be enrolled from 6 sites across Canada. Participants will be followed in the study for about 2 months.

Study Overview

• Status: Recruiting
• Conditions: End Stage Heart Failure
• Intervention / Treatment: Drug: Sildenafil Citrate

Detailed Description

Initially implanted as a bridge to transplantation, LVADs are increasingly used for the purpose of destination therapy. About 250 patients/year will receive LVAD device therapy in 12 implanting Canadian centres. Outcomes after LVAD implantation are critically dependent on right ventricular (RV) function. Development of right heart failure (RHF) in LVAD patients has a direct effect on mortality and is associated with a prolonged length of intensive care unit (ICU) and hospital admission. RHF in LVAD patients leads to increased morbidity and is associated with worse outcomes after cardiac transplantation. Despite improvements in surgical and medical management the incidence of RHF after LVAD implantation has plateaued at approximately 20-30%. A critical concept in the prevention of post-operative complications involves appropriate patient selection and prophylactic measures directed toward risk factors for development of RHF. To mitigate the risk of RHF after LVAD implantation, many implanting centres are increasingly utilizing pulmonary vasodilating agents in the post-operative period. Despite little evidence to support this approach, the phosphodiesterase-5A (PDE5) inhibitor Sildenafil is now empirically administered for reduction of PVR in some centres after LVAD implantation. Duration of therapy varies but may extend beyond 3 months and in some cases may continue indefinitely or until the time of heart transplant. A small, single-centre, open label study demonstrated that Sildenafil effectively reduced PVR in LVAD patients with persistent pulmonary hypertension post-operatively, however only hemodynamic endpoints were examined. Importantly, the investigation of this strategy was limited to those with elevated PAP, irrespective of their clinical condition or pre-implantation hemodynamic profile. There is a clear need for further research to establish the safety and efficacy of pulmonary vasodilators to either treat or prevent RHF in the LVAD patient population.

The investigators hypothesize that the vasodilatory effects of sildenafil can prevent or reverse the effects of elevated RV afterload and consequent RHF following LVAD implantation, and that preoperative initiation of therapy in an at-risk population is feasible and will be well tolerated. As such, there is a large potential for sildenafil to meet an unmet therapeutic need for patients following LVAD implantation.

The primary objective of this pilot study is to evaluate the tolerability and efficacy of sildenafil therapy initiated prior to and continued after LVAD implantation for the purpose of reducing PVR in patients at increased risk for development of RHF by INTERMACS criteria. The feasibility of introducing sildenafil in this clinical setting along with the ability to reduce PVR will be assessed.

Secondary Objectives: a) To determine the efficacy of sildenafil to reduce the need for prolonged inotropic support and post-operative ICU admission duration b) To determine the tolerability and feasibility of the proposed dosing strategy c) To determine the impact of sildenafil therapy on renal function and systemic arterial blood pressure d) To assess the impact of sildenafil therapy on the likelihood of development of post-operative RHF by INTERMACS criteria

STUDY METHODS:

1. Single-arm, open-label, prospective, multi-centre, interventional, feasibility and efficacy, pilot study of sildenafil in patients undergoing LVAD implantation.
2. This multi (6)-centre, Canadian trial is investigator initiated and industry sponsored. The study design, coordination and conduction and other study tasks including monitoring will be performed by the study investigators.

Following enrolment into the study, subjects will have their data (i.e. weight, blood pressure, pulse, lab work, medications, RHC data, ECG, physical exam), collected as standard-of-care (SOC), included in their study chart. Participants will be started on sildenafil at V1. If tolerated, subjects will be maintained on sildenafil pre and post-LVAD implementation. On day 14 (+/- 2 days) subjects will have a RHC to evaluate right heart function post-LVAD implantation. Subjects will return to the VAD (Ventricular Assist Device) Clinic for regular visits following discharge until day 55 (EOS) for similar data collection. Subjects will keep a daily sildenafil dosage diary from hospital discharge until day 55. Subjects will receive a brief telephone call at day 85 post LVAD implantation to evaluate safety and outcome data.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Nowell Fine, FRCPC; Phone Number: 403-956-3748; Email: nowell.fine@albertahealthservices.ca
• Study Contact Backup: Name: Jonathan Howlett, FRCPC; Phone Number: 403-944-3232; Email: howlettjonathan@gmail.com

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada
      • Recruiting
      • University of Calgary
      • Contact: Nowell Fine, FRCPC; Phone Number: 403.956.3748; Email: nowell.fine@albertahealthservices.ca
      • Contact: Leslie Jackson; Phone Number: 403.220.8709; Email: jacksola@ucalgary.ca
  • Manitoba
    • Winnipeg, Manitoba, Canada, R2H 2A6
      • Recruiting
      • St. Boniface Hospital
      • Contact: Wendy Janz; Phone Number: 204.237.2793; Email: wjanz@hsc.mb.ca
  • Ontario
    • London, Ontario, Canada, N6A 5A5
      • Recruiting
      • London Health Sciences Centre
      • Contact: Ryan Davey, FRCPC
      • Contact: Heather Hern; Phone Number: 32818 519.685.8500; Email: Heather.Hern@lhsc.on.ca
    • Ottawa, Ontario, Canada, K1Y 4W7
      • Recruiting
      • University of Ottawa Heart Institute
      • Contact: Allyson Thomas; Phone Number: 15011 613.696.7000; Email: athomas@ottawaheart.ca
      • Contact: Laura Menchini; Phone Number: 18089 613.696.7000; Email: lmenchini@ottawaheart.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients aged >18 years who are to receive durable (HeartMate II or III, or HeartWare HVAD) LVAD implantation for end-stage HF. Patients with all etiologies of HF will be included.
• Patients identified as having an increased risk for post-operative RHF using pre-operative hemodynamic assessment criteria, defined as the presence of ≥ 1 of the following: i) Central venous pressure (CVP):mean pulmonary capillary wedge pressure (PCWP) ratio ≥ 0.63 ii) RV stroke work index < 300 mmHg/mL/m2 iii) CVP ≥15 mmHg (CVP must be >8 mmHg if applying one of the other criteria) iv) Pre-operative PVR ≥ 3 Wood Units (240 dynes/cm5/sec)
• Systolic blood pressure ≥ 85 mmHg at study initiation
• Women of childbearing potential must have a negative pregnancy test. Women must not be breast feeding. Heterosexually active women of child bearing potential must use an effective method of contraception during the study.
• Ability to sign informed consent to participate

Exclusion Criteria:

• Preoperative INTERMACS level I or II
• Preoperative systemic hypotension with mean arterial pressure < 60 mmHg
• Planned insertion of RV support device (either temporary or permanent)
• Complex congenital heart disease where PVR measurement is not feasible or reliable (repaired or unrepaired)
• Right sided fixed or dynamic obstruction to blood flow (i.e., pulmonary stenosis) with resting gradient ≥ 10 mmHg.
• Previous organ transplantation
• Preoperative use of any oral pulmonary vasodilator therapy or oral/inhaled/nitrate therapy
• Patients requiring pre-operative hem - or peritoneal dialysis
• Pre-enrollment treatment with other pulmonary dilating agents such as other PDE5 inhibitors, endothelin antagonists, prostacyclin analogues. Use of postoperative nitric oxide will be permitted (although not concomitantly with the study medication) as clinically indicated in the postoperative setting
• Lack of ability to invasively measure right-sided pulmonary pressures
• Refusal or inability to sign informed consent
• Inability to accept preoperative study drug, or known sensitivity or allergy to sildenafil or any of its ingredients, or any other contra-indication to sildenafil as identified by product monograph
• Participation in any other current interventional (drug or device) study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: sildenafil citrate; Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.	Drug: Sildenafil Citrate; 20 mg tablets; Other Names: Revatio

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary vascular resistance (PVR)	Change in PVR reported in Wood Units as measured invasively via right heart catheterization (RHC)	From baseline to postoperative day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Right heart failure (RHF)	Proportion of participants experiencing RHF defined as INTERMACS criteria: i) Requirement of continuous-flow right ventricular assist device (RVAD) implantation for hemodynamic support any time prior to study end	From baseline to day 55 (end of study)
RHF	Proportion of participants experiencing RHF defined as INTERMACS criteria: ii) Prolonged inotropic support beyond postoperative day 14 directed for clinical RHF	Postoperative day 14 to postoperative day 55 (end of study)
RHF	Proportion of participants experiencing RHF defined as INTERMACS criteria: iii) Discontinuation of study drug for the purpose of introduction of additional pulmonary vasodilator for the purpose of treatment of clinical RHF at any time during the study protocol	From baseline to postoperative day 55 (end of study)
Inotrope requirement	Proportion of patients requiring any inotrope medication at study end	From baseline to day 55 (study end)
ICU	Total number of hours in ICU by study end	From baseline to day 55 (end of study)
Hospitalization	Total hospital length of stay by study end	From baseline to day 55 (end of study)

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety: Drug interruptions	Proportion of patients with temporary or permanent study drug interruptions	From baseline to day 55 (study end)
Safety: Renal	Proportion of patients requiring renal replacement therapy or doubling of serum creatinine	From baseline to day 55 (study end)
Safety: All-cause mortality	All-cause mortality at study end	From enrollment to day 85 (final SAE review)
Safety: Transfusion	Total number of units of packed red cells transfused during hospital stay	From baseline to hospital discharge
Safety: GFR	Greatest percentage increase in glomerular filtration rate from baseline at any time during study	From baseline fo day 55 (study end)
Safety: Mean arterial pressure	Mean arterial pressure	At ICU discharge and at day 55 (study end)
Safety: Symptomatic hypotension	Proportion of patients with > or = 1 episodes of symptomatic hypotension (syncope or orthostatic hypotension)	From baseline to day 55 (study end)
Safety: Liver enzymes	Increase in hepatic enzymes > or = 2x baseline (preoperative) levels	From baseline to day 55 (study end)
Safety: Pump time	Total cardiac surgical bypass pump time	LVAD implantation day
Safety: Adverse drug reactions	Any and all adverse drug reactions	From baseline to day 85 (final SAE review)

Collaborators and Investigators

• Sponsor: University of Calgary
• Collaborators: Pfizer
• Investigators: Principal Investigator: Jonathan Howlett, FRCPC, University of Calgary

Study record dates

Study Major Dates

• Study Start (Actual): March 12, 2018
• Primary Completion (Anticipated): September 30, 2021
• Study Completion (Anticipated): January 1, 2022

Study Registration Dates

• First Submitted: November 22, 2017
• First Submitted That Met QC Criteria: November 22, 2017
• First Posted (Actual): November 29, 2017

Study Record Updates

• Last Update Posted (Actual): April 29, 2021
• Last Update Submitted That Met QC Criteria: April 28, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Urological Agents; Enzyme Inhibitors; Phosphodiesterase Inhibitors; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate
• Other Study ID Numbers: RVD102017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No